Sennesael J J, Lamote J G, Violet I, Tasse S, Verbeelen D L
Renal Unit, Academisch Ziekenhuis, Vrije Universiteit Brussel, Belgium.
Am J Kidney Dis. 1996 May;27(5):701-8. doi: 10.1016/s0272-6386(96)90106-7.
The effects of amlodipine and perindopril on renal hemodynamics and tubular function in cyclosporine-treated hypertensive renal allograft recipients were evaluated in a randomized, double-blind crossover fashion. Ten patients were studied after a 2-week placebo run-in and, after 8 weeks of active treatment, allowing a 2-week placebo washout between treatments. At the end of each period, glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured as 51Cr-EDTA and 123I-hippuran clearance, respectively, and tubular function evaluated by the lithium clearance technique was determined. Both drugs maintained GFR and ERPF and lowered mean arterial pressure (MAP, mm Hg) to a similar extent (time x treatment, P = 0.466): amlodipine from 126.9 +/- 2.5 to 115.9 +/- 2.2; perindopril from 126.9 +/- 2.5 to 117.9 +/- 3.9 (time effect of all treatments together, P = 0.003). Accordingly, renal vascular resistance (RVR, mm Hg/mL/min/1.73 m2) was equally reduced (time x treatment, P = 0.955): amlodipine from 0.36 +/- 0.03 to 0.30 +/- 0.02; perindopril from 0.36 +/- 0.03 to 0.32 +/- 0.01 (time effect all treatments together, P = 0.043). Sodium clearance and fractional excretion of sodium were not affected by either drug. Output of fluid from the proximal tubules measured as clearance of lithium (CLi, mL/min) and uric acid (CUr, mL/min) was higher after amlodipine than after perindopril (CLi 19.1 +/- 2.1 v 16.5 +/- 1.7, P =0.036 and CUr 7.0 +/- 0.6 v 5.9 +/- 0.4, P = 0.007). As a consequence, after amlodipine, distal absolute reabsorption of sodium was higher (DARNa 2.57 +/- 0.28 v 2.19 +/- 0.22 mEq/min, P = 0.027) and serum uric acid was lower (5.9 +/- 0.3 v 6.7 +/- 0.4 mg/dL, P = 0.001) in comparison with perindopril. In cyclosporine-treated renal allograft hypertensives, amlodipine and perindopril lower blood pressure equally and reduce RVR to the same extent. Overall sodium excretion is not affected by either agent. Urate clearance is higher and serum uric acid lower on amlodipine as compared with perindopril.
以随机、双盲交叉方式评估氨氯地平和培哚普利对接受环孢素治疗的高血压肾移植受者肾血流动力学和肾小管功能的影响。10名患者在经过2周的安慰剂导入期后进行研究,在8周的积极治疗后,治疗之间允许有2周的安慰剂洗脱期。在每个阶段结束时,分别通过51Cr-EDTA和123I-马尿酸清除率测量肾小球滤过率(GFR)和有效肾血浆流量(ERPF),并通过锂清除技术评估肾小管功能。两种药物均维持GFR和ERPF,并将平均动脉压(MAP,mmHg)降低到相似程度(时间×治疗,P = 0.466):氨氯地平从126.9±2.5降至115.9±2.2;培哚普利从126.9±2.5降至117.9±3.9(所有治疗的时间效应,P = 0.003)。因此,肾血管阻力(RVR,mmHg/mL/min/1.73 m2)同样降低(时间×治疗,P = 0.955):氨氯地平从0.36±0.03降至0.30±0.02;培哚普利从0.36±0.03降至0.32±0.01(所有治疗的时间效应,P = 0.043)。两种药物均未影响钠清除率和钠分数排泄。以锂清除率(CLi,mL/min)和尿酸清除率(CUr,mL/min)衡量的近端肾小管液体输出在氨氯地平治疗后高于培哚普利治疗后(CLi 19.1±2.1对16.5±1.7,P = 0.036;CUr 7.0±0.6对5.9±0.4,P = 0.007)。因此,与培哚普利相比,氨氯地平治疗后远端钠绝对重吸收更高(DARNa 2.57±0.28对2.19±0.22 mEq/min,P = 0.027),血清尿酸更低(5.9±0.3对6.7±0.4 mg/dL,P = 0.001)。在接受环孢素治疗的肾移植高血压患者中,氨氯地平和培哚普利降压效果相同,降低RVR的程度相同。两种药物均不影响总体钠排泄。与培哚普利相比,氨氯地平的尿酸清除率更高,血清尿酸更低。